Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669286 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL708662 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL11882735 | 0.84 | LMNA (0.35) | LMNAL3MBTL1TDP1 | |
| SCHEMBL3501009 | 0.70 | ALDH1A1 (0.42) | LMNAL3MBTL1TDP1 | |
| Mannitol SCHEMBL23066399 | 0.69 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL2477078 | 0.69 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL2297640 | 0.69 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20594082 | 0.69 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20567656 | 0.69 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL763 | 0.69 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606020-B1 | METHOD OF SYNTHESIS OF SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL | DEL MAR PHARMACEUTICALS (CA) | 2018-12-26 | — | — | EP | claimed |
| EP-2758043-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIBROMODULCITOL | Brown, Dennis M. (US) | 2014-07-30 | — | — | EP | claimed |
| WO-2014081405-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIBROMODULCITOL | BROWN DENNIS (US) | 2014-05-30 | — | — | WO | claimed |
| US-8563758-B2 | Method of synthesis of substituted hexitols such as dianhydrogalactitol | DEL MAR PHARMACEUTICALS (CA) | 2013-10-22 | — | — | US | claimed |
| US-20130211111-A1 | METHOD OF SYNTHESIS OF SUBSTISTUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL | DEL MAR PHARMACEUTICALS (CA) | 2013-08-15 | — | — | US | claimed |
| EP-2606020-A2 | METHOD OF SYNTHESIS OF SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL | Del Mar Pharmaceuticals (CA) | 2013-06-26 | — | — | EP | claimed |
| WO-2012024368-A2 | METHOD OF SYNTHESIS OF SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL | DEL MAR PHARMACEUTICALS (CA) | 2012-02-23 | — | — | WO | claimed |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | BROWN DENNIS (US) | 2025-01-14 | — | — | US | disclosed |
| EP-2804602-B1 | USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTFORME AND MEDULLOBLASTOMA | DEL MAR PHARMACEUTICALS (CA) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024098032-A1 | USE OF DIANHYDROGALACTITOL IN TREATING EPENDYMOMA | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2024-05-10 | — | — | WO | disclosed |
| US-20230338325-A1 | DIANHYDROGALACTITOL FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMAS | DEL MAR PHARMACEUTICALS (BC) LIMITED (CA) | 2023-10-26 | — | — | US | disclosed |
| US-11717505-B2 | Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas | DEL MAR PHARMACEUTICALS (BC) LIMITED (CA) | 2023-08-08 | — | — | US | disclosed |
| CN-115813902-A | Use of substituted hexitols for the treatment of malignant tumors | 德玛公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20130211111-A1 | METHOD OF SYNTHESIS OF SUBSTISTUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL | DEL MAR PHARMACEUTICALS (CA) | 2013-08-15 | — | — | US | disclosed |
| WO-2013110058-A2 | USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTFORME AND MEDULLOBLASTOMA | BACHA JEFFREY (CA) | 2013-07-25 | — | — | WO | disclosed |
| EP-2606020-A2 | METHOD OF SYNTHESIS OF SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL | Del Mar Pharmaceuticals (CA) | 2013-06-26 | — | — | EP | disclosed |
| EP-2606020-A2 | METHOD OF SYNTHESIS OF SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL | Del Mar Pharmaceuticals (CA) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024368-A3 | METHOD OF SYNTHESIS OF SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL | DEL MAR PHARMACEUTICALS (CA) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012024368-A2 | METHOD OF SYNTHESIS OF SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL | DEL MAR PHARMACEUTICALS (CA) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024368-A2 | METHOD OF SYNTHESIS OF SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL | DEL MAR PHARMACEUTICALS (CA) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338325-A1 | DIANHYDROGALACTITOL FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMAS | WEE1, WEE2, PYGB | LMNA 4026/4885L3MBTL1 2321/4885TDP1 34/4885 |
| US-11717505-B2 | Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas | WEE1, WEE2, DCK | LMNA 4002/4885L3MBTL1 1521/4885TDP1 68/4885 |
| US-20130211111-A1 | METHOD OF SYNTHESIS OF SUBSTISTUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL | DDOST, DAD1, AGL | LMNA 1893/4885L3MBTL1 3238/4885TDP1 911/4885 |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | HEXD, DDOST, PAICS | LMNA 2797/4885L3MBTL1 1305/4885TDP1 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.